Literature DB >> 15450729

Inhibitory targeting of checkpoint kinase signaling overrides radiation-induced cell cycle gene regulation: a therapeutic strategy in tumor cell radiosensitization?

Anne Hansen Ree1, Ase Bratland, Ragnhild V Nome, Trond Stokke, Oystein Fodstad, Yvonne Andersson.   

Abstract

BACKGROUND AND
PURPOSE: The tumor cell defense response to ionizing radiation involves a temporary arrest at the cell cycle G(2) checkpoint, which is activated by a signaling cascade initiated by the ATM kinase response to DNA damage, ultimately leading to the outcome of further cell survival if the DNA is properly repaired. The inhibitory targeting of the checkpoint kinase signaling elicited by ATM may define a biologically based strategy to override the G(2) phase delay that prevents mitotic entry after DNA damage, thereby increasing the probability of mitotic cell death following exposure to ionizing radiation.
MATERIALS AND METHODS: Breast carcinoma cell lines with intact or defective function of the tumor-suppressor protein BRCA1 were exposed to ionizing radiation in the absence or presence of a specific inhibitor (UCN-01) of the checkpoint kinase CHK1, and the response profiles of cell cycle distribution and G(2) phase regulatory factors, as well as the efficiency of clonogenic regrowth, were analyzed.
RESULTS: The radiation-induced G(2) phase accumulation was preceded by a transient down-regulation of the G(2) phase-specific polo-like kinase-1 and cyclin B1, which required intact function of both BRCA1 and CHK1. The concomitant treatment with UCN-01 seemed to amplify the cytotoxic effect of ionizing radiation on clonogenic regrowth.
CONCLUSION: The effector mechanism of DNA damage on cell cycle gene regulation signals through the checkpoint kinase network. Among molecular cell cycle-targeted drugs currently in pipeline for testing in early phase clinical trials, CHK1 inhibitors may have therapeutic potential as radiosensitizers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15450729     DOI: 10.1016/j.radonc.2004.07.002

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  5 in total

1.  G2 checkpoint abrogator abates the antagonistic interaction between antimicrotubule drugs and radiation therapy.

Authors:  Meihua Sui; Hongfang Zhang; Xiaoyun Di; Jinjia Chang; Youqing Shen; Weimin Fan
Journal:  Radiother Oncol       Date:  2012-06-09       Impact factor: 6.280

Review 2.  New molecular targets in radiotherapy: DNA damage signalling and repair in targeted and non-targeted cells.

Authors:  Susanne Burdak-Rothkamm; Kevin M Prise
Journal:  Eur J Pharmacol       Date:  2009-10-14       Impact factor: 4.432

3.  Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition.

Authors:  Kjersti Flatmark; Ragnhild V Nome; Sigurd Folkvord; Ase Bratland; Heidi Rasmussen; Mali Strand Ellefsen; Øystein Fodstad; Anne Hansen Ree
Journal:  Radiat Oncol       Date:  2006-08-03       Impact factor: 3.481

4.  Enhancement of recombinant myricetin on the radiosensitivity of lung cancer A549 and H1299 cells.

Authors:  Shijie Zhang; Lei Wang; Hongchun Liu; Guoqiang Zhao; Liang Ming
Journal:  Diagn Pathol       Date:  2014-03-20       Impact factor: 2.644

5.  Identification of biomarker microRNAs for predicting the response of colorectal cancer to neoadjuvant chemoradiotherapy based on microRNA regulatory network.

Authors:  Yaqun Zhu; Qiliang Peng; Yuxin Lin; Li Zou; Peipei Shen; Feifei Chen; Ming Min; Li Shen; Jiajia Chen; Bairong Shen
Journal:  Oncotarget       Date:  2017-01-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.